Hughes riskApps[™] and PenRad[™] integration

PenRad now offers an interface to the Hughes riskApps[™] cancer risk model and patient survey. This integration expands the access PenRad customers have to various risk models helping to identify and manage women at high risk for hereditary cancer.

Hughes riskApps[™] calculates additional risk factors beyond the risk models available in most mammography information systems. The Hughes riskApps[™] and patient kiosk/tablet survey software connects to PenRad's database, eliminating the need for duplicated data entry. The patient survey application can be used as a paperless survey for breast centers instead of an interactive interview with the patient. Extended risk assessment models can provide facilities additional data to qualify recommendations for BRCA testing, MRI, BSGI, MBI and full breast ultrasound exams.

Hughes riskApps[™] was originally conceived and developed by Kevin S. Hughes, MD and Sherwood S. Hughes of the Massachusetts General Hospital to identify and manage women at high risk for hereditary cancer. The application is the work of a consortium of the Massachusetts General Hospital, the University of Massachusetts at Lowell, and the Newton-Wellesley Hospital.

The system offers a patient populated survey of his or her own family history and risk data using a wireless touch tablet or kiosk PC (in various languages) or input and review by a clinical staff member. When using is wireless tablet, no patient data resides on the tablet eliminating concern of data loss or an inadvertent HIPPA violation.



Once the survey data is received it is analyzed for BRCA1 & 2, MLH1, 2, 6 mutations as well as for breast, colorectal, endometrial, ovarian cancer risk, for five year and life time percentages.

In addition, the Hughes riskApps[™] application generates a graphical pedigree of family history, recap family history, and risk calculation results in numerical and graphical formats available on screen or as a report printout. Results include output from the BayesMendel models, BRCAPRO, CLAUS, GAIL and MYRIAD models.

The BayesMendel model calculates risk for several cancer risk models, including breast, ovarian, colorectal, endometrial, and pancreatic cancers, as well as melanoma. It does this by invoking the BRCAPro, MMRPro, PancPro, and MelaPro BayesMendel risk calculation models. These risk models are jointly included in a set of software algorithms known as the BayesMendel R package, that is maintained by Dr. Parmigiani and colleagues of the Dana-Farber Cancer Institute. These algorithms take family history data such as disease occurrences in family members, genetic test result data, and tumor marker data, and calculate probabilities for genetic mutation as well as probabilities for cancer in various time periods.



Senetic Testing				S	mthesis of	Mutation Re	de-
Gudeli	ne Teding nut recoherended		Probabil	w -0	and the second		
linician's Recommendati	0.8 Testing nut reconvended		Of Muter	ion (A			
Patient's Preferen	ce agres with recommendation			BBC	APRO 4%		
BOCLOON A	In Data Cost	difference Transfer	terr later 1	Myr	iad: 6.9%		
base interesting the	animitate Gall Claus Myra	o (vanvenabi i acie) i in	ore mo				
Dream Overs							
Percent Char	nce of Breast Cancer						
100			1. 34		Inte	rventions	10 0000
1.00		19	2 4 4	MRI	Nammo	Prevention	Prophylactic Mastectomy
3		118	RCA1 Posi	live	1	1	
1		40	100%	Yearly	Yearly	Tancoferi	Consider
1		Bas	ed on Can	ent Synthes	is of Risk	\$	
40	-	127	41	No	Yearly	No	No
And		119	RCA1 and	BRCA2 Nega	rive)}2	
20 LAY Screep Th	valuet	1	15	No	Yeaty	No	No
		100	rage Pape	dation	1	-	
50 55	40 65 70 75 8	10 1/2 1/0	1 55	No	Teaty	1 NH	No
	rige of Patient	Eth	nicity used	I for BRCA	PRO: White		
Exit					e Bar		Next >
2222							
English 💻 Spa	nish II Italian	sk Asses	sme	ent S	urve	y ^{hu}	g hes riskA
English 💻 Spa	nish I I talian Cancer Ris	sk Asses	sme	ent S	urve	y ^{hu}	g hes riskA
English 🚾 Spa	nish II Italian Cancer Ris Are you	s k Asses still having	sme you	ent S	urve	y ^{hu}	ghes risk A
English 💶 Spa	nish II Italian Cancer Ris Are you	s k Asses still having	sme you	ent S	urve ods?	y ^{hu} i	ghes riskA
English 💶 Spa	nish II Italian Cancer Ris Are you	sk Asses	sme you	ent S	urve ods?	y ^{hu}	ghes riskA
English 💻 Spa	nish II Italian Cancer Ris Are you	s k Asses still having	sme you	ent S	urve ods?	y ^{hu}	ghes riskA
English 💶 Spa	nish I Italian Cancer Ris Are you	sk Asses	sme you	ent S	urve ods?	y hu	ghes riskA
English <u></u> Spa	nish I talian Cancer Ris Are you	sk Asses	sme you	ent S	urve ods?	y hu	ghes riskA
English 💶 Spa	nish I Italian Cancer Ris Are you	sk Asses	sme you	ent S	urve ods?	y ^{hu} i	ghes riskA
English <u></u> Spa	nish I Italian Cancer Ris Are you	sk Asses still having	sme you	ent S	urve	y ^{hu}	ghes riskA
English I Spa	nish II talian Cancer Ris Are you	sk Asses still having Ye	sme you	ent S	urve	y ^{hu}	ghes riskA
English 💶 Spa	nish II Italian Cancer Ris Are you	sk Asses still having Ye	sme you	ent S	urve ods?	y hu	ghes riskA
English 💶 Spa	nish II Italian Cancer Ris Are you :	sk Asses still having Ye No	sme your	ent S	urve ods?	y ^{hu}	ghes riskA
English ᆂ Spa	nish II Italian Cancer Ris Are you	sk Asses still having Ye No	sme your	ent S	urve ods?	y ^{hu}	ghes riskA
English 💶 Spa	nish II Italian Cancer Ris Are you :	sk Asses still having Ye Not s	sme youi s	ent S	urve	y ^{hu}	ghes risk A
English <u>s</u> spa	nish II Italian Cancer Ris Are you :	sk Asses still having Ye Not s	you you s	ent S	urve	y ^{hu}	ghes riskA
English <u></u> spa	nish II Italian Cancer Ris Are you	sk Asses still having Ye Not s	sme your s) ure ar	ent S	urve	y hu	ghes riskA
English <u>s</u> sp	nish II italian Cancer Ris Are you :	still having	your your s ure ar	ent S	urve	y hu	ghes riskA
English <u>s</u> spi	nish II Italian Cancer Ris Are you :	sk Asses still having Ye Not s Clea	your your ss) ure ar	ent S	urve	y ^{hu}	ghes riskA
English <u>s</u> spa	nish II falian Cancer Ris Are you :	still having	your your s ure ar	ent S	urve ods?	y hu	ghesriskA
English 🔽 Spir	nish II falian Cancer Ris Are you :	sk Asses still having Ye Not s Clea	your your s) ure ar	r perio	urve,	y hu	ghes riskA

Clinician Application

The Hughes riskApps[™] Clinician Application provides physicians and clinic staff the ability to interact with patient data, run breast, ovarian and colorectal cancer risk calculations, print surveys with graphical pedigrees and letters for patients and referring physicians. Extended risk functionality allows for entering additional information related to genetic testing of patients and family members as well as decision support for future treatment plans of high risk patients.

Tablet Application

The Hughes riskApps[™] tablet application allows patients to navigate a questionnaire and provide answers to both family history and life style questions.

The Standard questionnaire, which takes 2 to 4 minutes to complete is a basic set of questions aimed at identifying patients who are at potentially high risk. High risk patients may then be referred to a high risk clinic program where they can answer the Risk Clinic questionnaire which takes 10 to 20 minutes to complete varying on the complexity of a patient's family history.

On subsequent visits, prior survey data is pulled forward and patients are allowed to change or add information. Based on a series of internal thresholds the survey expands to collect more specific data for hereditary risk assessment when applicable. The Risk Clinic questionnaire collects more detailed information about family members, diseases, age of onset and current status. Clinicians may also enter or review the data through the clinician application during one on one interviews.

To learn more about the Hughes riskApps[™] products go to www.hughesriskapps.net

PenRad Mammography solutions enhance the workflow, quality and revenue of your practice by optimizing the management of clinical information. Aggregation and standardization of multimodality reading, reporting, tracking and management in PenRad provides unparalleled workflow benefits without reinvestment in RIS, HIS, PACS or other IT solutions. PenRad is your sole source provider for mammography information data management, analysis and workflow.

To find out more about any of the PenRad solutions contact us at 763.475.3388, visit us on the web at www.penrad.com or email us: info@penrad.com. Alternatively you can fax this form back to us at 763.475.2815.

Have a sales representative car	all me to discuss PenRad solutions.
---------------------------------	-------------------------------------

ŀ	lave an	applications	person co	ontact me t	o set up a	a demonstration.

Name	 		Phone
Facility name	 		email
	_	TM	

